Arabako Erakunde Sanitario Integratua
Osakidetzako erakundea
Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas
Madrid, EspañaCentro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas-ko ikertzaileekin lankidetzan egindako argitalpenak (17)
2024
-
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry
Therapeutic Advances in Gastroenterology, Vol. 17
-
Endoscopic surveillance for familial intestinal gastric cancer in low-incidence areas: An effective strategy
International Journal of Cancer, Vol. 154, Núm. 1, pp. 124-132
-
Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry
Digestive Diseases, Vol. 42, Núm. 3, pp. 257-264
-
Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU
Digestive and Liver Disease, Vol. 56, Núm. 11, pp. 1845-1853
-
Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA
Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290
2022
-
An NMR-Based Model to Investigate the Metabolic Phenoreversion of COVID-19 Patients throughout a Longitudinal Study
Metabolites, Vol. 12, Núm. 12
-
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study
Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736
-
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
Journal of Clinical Medicine, Vol. 11, Núm. 15
2021
-
Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry
Digestive Diseases and Sciences, Vol. 66, Núm. 6, pp. 2014-2023
-
Impact of biological agents on postsurgical complications in inflammatory bowel disease: A multicentre study of geteccu
Journal of Clinical Medicine, Vol. 10, Núm. 19
2020
-
Copy-number alteration burden differentially impacts immune profiles and molecular features of hepatocellular carcinoma
Clinical Cancer Research, Vol. 26, Núm. 23, pp. 6350-6361
-
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry
Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616
2019
-
Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results from the ENEIDA Registry
Inflammatory Bowel Diseases, Vol. 25, Núm. 11, pp. 1862-1870
-
Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial
Therapeutic Advances in Gastroenterology, Vol. 12
2010
-
Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy
Antiviral Therapy, Vol. 15, Núm. 6, pp. 881-886
2009
-
Rate and timing of hepatitis c virus relapse after a successful course of pegylated interferon plus ribavirin in hiv-infected and hiv-uninfected patients
Clinical Infectious Diseases, Vol. 49, Núm. 9, pp. 1397-1401
2008
-
Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C
AIDS, Vol. 22, Núm. 1, pp. 15-21